Baseline characteristics when infliximab therapy was initiated
| Patient | Sex | Smoking | Age | Duration | Scadding | EPM | Treatment indication | Treatment | BAL |
| 1 | M | No | 53 | 20 | IV | Peripheral lymph nodes | Pulmonary | P | x |
| 2 | M | No | 40 | 5 | I | Ocular | Fatigue, joint pain | P | x |
| 3 | M | No | 46 | 3 | II | 0 | Pulmonary | P | x |
| 4 | M | No | 42 | 2 | II | 0 | Pulmonary | P | 0 |
| 5 | F | No | 42 | 12 | IV | 0 | Pulmonary | P | 0 |
| 6 | F | No | 55 | 3 | I | Skin | Fatigue | P | x |
| 7 | M | No | 44 | 9 | III | Hypercalciuria | Pulmonary | P | x |
| 8 | M | No | 44 | 4 | II | 0 | Pulmonary | M | x |
| 9 | M | No | 50 | 4 | IV | 0 | Pulmonary | P | x |
| 10 | M | No | 55 | 2 | II | Skin | Pulmonary | P | x |
| 11 | M | No | 51 | 6 | IV | 0 | Pulmonary | P | x |
| 12 | F | Yes | 42 | 2 | II | 0 | Pulmonary | M | 0 |
| 13 | M | Yes | 34 | 6 | II | Peripheral lymph nodes | Pulmonary | M | 0 |
| 14 | M | No | 51 | 7 | IV | 0 | Pulmonary | P | x |
| 15 | M | Yes | 49 | 4 | II | 0 | Pulmonary | 0 | x |
Baseline characteristics when infliximab therapy was initiated. Smoking=current smoking habits, no=not a current smoker, yes=current smoker; duration=duration of sarcoidosis in years before infliximab treatment started; treatment indication=which symptoms that were the reason for initiation of infliximab treatment; Scadding=Scadding stage=radiographic extent of sarcoidosis assessed by chest X-ray (0–IV); treatment=concomitant treatment during infliximab treatment. P, M and 0 denote prednisone, methotrexate and no concomitant treatment, respectively. The x and 0 in the BAL column represent if patient is included in BALF data analysis (x) or not (0).
BAL, bronchoalveolar lavage; BALF, BAL fluid; EPM, extrapulmonary manifestations; F, female; M, male.